Twenty-nine ( 4.9 % ) patients exhibited adverse reactions , 55.2 % exhibited excitation , 20.7 % suffered from insomnia , 10.3 % had headaches , 3.4 % had erythra , 3.4 % suffered from abdominal pain , and 3.4 % exhibited an increased glutamic-pyruvate transaminase level .